GlassScriptPhysician profile
Todd C Hoopman
NPI 1275663361
$76,421.91
in general payments reported to CMS, 2019-2025
27 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,756 · 2020: $11K · 2021: $1,600 · 2022: $5,067 · 2023: $12K · 2024: $31K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $22K · Travel and Lodging: $2,627 · Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,661.00 |
| Consulting Fee | $21,500.00 |
| Travel and Lodging | $2,626.91 |
| Food and Beverage | $1,258.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $59,181.57 | 2021-2025 | Illumisite, Arcpoint |
| Covidien LP | $15,163.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $587.06 | 2019-2021 | |
| Glaxosmithkline, LLC. | $201.72 | 2019-2020 | |
| Cytovale, INC. | $146.93 | 2025 | |
| Genentech USA, INC. | $146.06 | 2019-2020 | |
| Pulmonx Corporation | $144.66 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $81.58 | 2019-2020 | |
| Insmed, INC. | $75.11 | 2020-2022 | |
| Grifols USA, LLC | $64.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $59.14 | 2019-2020 | |
| Gilead Sciences, INC. | $55.05 | 2019 | |
| Philips North America LLC | $49.04 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.59 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $42.14 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $41.06 | 2019 | |
| Advanced Respiratory, INC | $35.11 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $33.11 | 2019 | |
| Mylan Specialty L.P. | $29.85 | 2019-2020 | |
| Electromed, INC. | $29.48 | 2023 | Smartvest |
| Shire North American Group INC | $19.75 | 2019 | |
| Genzyme Corporation | $19.03 | 2019 | |
| Allergan, INC. | $17.80 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.61 | 2019 | |
| Pfizer INC. | $16.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Hoopman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.